CSTL · Insider Trading
Castle Biosciences, Inc. Common Stock
Every open-market purchase and sale reported by CSTL officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-11-18 | Derek J Maetzold | Pres. & Chief Exec. Officer | Sell | −6,942 | −$228.53K |
| 2026-11-13 | Tobin W Juvenal | Chief Commercial Officer | MIXED | — | −$17.80K |
| 2026-11-12 | Tobin W Juvenal | Chief Commercial Officer | Sell | −6,116 | −$206.52K |
| 2026-11-04 | Derek J Maetzold | Pres. & Chief Exec. Officer | Sell | −14,496 | −$523.33K |
| 2026-10-30 | Tobin W Juvenal | Chief Commercial Officer | Sell | −6,578 | −$239.59K |
| 2026-10-28 | Tobin W Juvenal | Chief Commercial Officer | Sell | −3,288 | −$108.77K |
| 2026-10-21 | Derek J Maetzold | Pres. & Chief Exec. Officer | Sell | −14,496 | −$462.57K |
| 2026-10-14 | Tobin W Juvenal | Chief Commercial Officer | Sell | −3,288 | −$110.61K |
| 2026-10-07 | Derek J Maetzold | Pres. & Chief Exec. Officer | MIXED | −6,331 | −$496.05K |
| 2026-10-05 | Kristen M Oelschlager | Chief Operating Officer | MIXED | — | −$135.28K |
| 2026-10-01 | Tobin W Juvenal | Chief Commercial Officer | Sell | −6,577 | −$232.13K |
| 2026-09-23 | Derek J Maetzold | Pres. & Chief Exec. Officer | MIXED | −5,916 | −$491.70K |
| 2026-09-16 | Tobin W Juvenal | Chief Commercial Officer | Sell | −6,600 | −$222.62K |
| 2026-09-15 | Derek J Maetzold | Pres. & Chief Exec. Officer | MIXED | −5,934 | −$444.35K |
| 2026-09-03 | Kristen M Oelschlager | Chief Operating Officer | MIXED | — | −$124.61K |
| 2026-09-02 | Tobin W Juvenal | Chief Commercial Officer | Sell | −1,730 | −$56.76K |
| 2026-09-01 | Derek J Maetzold | Pres. & Chief Exec. Officer | MIXED | −6,132 | −$586.43K |
| 2026-08-27 | Tobin W Juvenal | Chief Commercial Officer | Sell | −9,050 | −$317.11K |
| 2026-08-26 | Kristen M Oelschlager | Chief Operating Officer | Sell | −24,602 | −$837.86K |
| 2026-08-19 | Tobin W Juvenal | Chief Commercial Officer | Sell | −1,730 | −$51.19K |
| 2026-08-18 | Frank Stokes | Chief Financial Officer | Sell | −24,908 | −$741.51K |
| 2026-08-18 | Derek J Maetzold | Pres. & Chief Exec. Officer | MIXED | −6,132 | −$214.48K |
| 2026-08-06 | Tobin W Juvenal | Chief Commercial Officer | Sell | −1,301 | −$49.95K |
| 2026-08-06 | Derek J Maetzold | Pres. & Chief Exec. Officer | MIXED | −16,114 | −$1.16M |
| 2026-08-05 | Kristen M Oelschlager | Chief Operating Officer | Sell | −8,586 | −$255.62K |
| 2026-08-04 | Tobin W Juvenal | Chief Commercial Officer | Sell | −19,040 | −$556.17K |
| 2026-08-04 | Derek J Maetzold | Pres. & Chief Exec. Officer | MIXED | −11,502 | −$826.48K |
| 2026-07-29 | Derek J Maetzold | Pres. & Chief Exec. Officer | MIXED | −3,622 | −$222.83K |
| 2026-07-16 | Derek J Maetzold | Pres. & Chief Exec. Officer | MIXED | −3,622 | −$94.31K |
| 2026-07-06 | Kristen M Oelschlager | Chief Operating Officer | Sell | −8,586 | −$209.65K |
| 2026-07-06 | Derek J Maetzold | Pres. & Chief Exec. Officer | MIXED | −3,622 | −$224.06K |
| 2026-06-18 | Kristen M Oelschlager | Chief Operating Officer | Sell | −8,587 | −$177.84K |
| 2026-06-17 | Derek J Maetzold | Pres. & Chief Exec. Officer | MIXED | −3,622 | −$84.88K |
| 2026-06-03 | Derek J Maetzold | Pres. & Chief Exec. Officer | MIXED | −3,622 | −$190.30K |
| 2026-06-01 | Daniel Bradbury | Director | A | +11,766 deriv. | — |
| 2026-06-01 | Rodney Cotton | Director | A | +11,766 deriv. | — |
| 2026-06-01 | G Bradley Cole | Director | A | +11,766 deriv. | — |
| 2026-06-01 | Ellen Goldberg | Director | A | +11,766 deriv. | — |
| 2026-06-01 | Miles Harrison | Director | A | +11,766 deriv. | — |
| 2026-06-01 | Kim Caple | Director | A | +11,766 deriv. | — |
| 2026-06-01 | Tiffany Olson | Director | A | +11,766 deriv. | — |
| 2026-05-27 | Kim Caple | Director | M | +13,667 | — |
| 2026-05-27 | Ellen Goldberg | Director | M | +13,667 | — |
| 2026-05-27 | Tiffany Olson | Director | M | +13,667 | — |
| 2026-05-27 | Miles Harrison | Director | M | +13,667 | — |
| 2026-05-27 | Daniel Bradbury | Director | M | +13,667 | — |
| 2026-05-27 | G Bradley Cole | Director | M | +13,667 | — |
| 2026-05-27 | Rodney Cotton | Director | M | +13,667 | — |
| 2026-05-26 | Tobin W Juvenal | Chief Commercial Officer | M | +11,210 | +$37.89K |
| 2026-05-22 | Derek J Maetzold | Pres. & Chief Exec. Officer | MIXED | −3,622 | −$82.75K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Derek J Maetzold | Pres. & Chief Exec. Officer | 149,000 | $5.03M |
| Kristen M Oelschlager | Chief Operating Officer | 87,351 | $2.95M |
| Ellen Goldberg | Director | 40,921 | $1.38M |
| Tiffany Olson | Director | 39,573 | $1.34M |
| Kim Caple | Director | 36,121 | $1.22M |
| Daniel Bradbury | Director | 35,631 | $1.20M |
| Miles Harrison | Director | 35,631 | $1.20M |
| Frank Stokes | Chief Financial Officer | 35,177 | $1.19M |
| Tobin W Juvenal | Chief Commercial Officer | 34,967 | $1.18M |
| Rodney Cotton | Director | 32,998 | $1.12M |
| G Bradley Cole | Director | 32,976 | $1.11M |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CSTL quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.